- Full Year 2024 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2024
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2024
- Q3 2024 Eisai Co Ltd Earnings Presentation TranscriptFeb 06, 2024
- Eisai Co Ltd Launch of LEQEMBI in Japan TranscriptDec 13, 2023
- Q2 2024 Eisai Co Ltd Earnings Presentation TranscriptNov 07, 2023
- Q1 2024 Eisai Co Ltd Earnings Presentation TranscriptAug 02, 2023
- Eisai Co Ltd Media and Investor Conference TranscriptJul 07, 2023
- Full Year 2023 Eisai Co Ltd Earnings Presentation TranscriptMay 15, 2023
- Eisai Co Ltd Information Meeting TranscriptMar 10, 2023
- Q3 2023 Eisai Co Ltd Earnings Call TranscriptFeb 06, 2023$61.5Earnings
- Eisai Co Ltd Approach to US Pricing for LEQEMBI Briefing TranscriptJan 07, 2023
- Eisai Co Ltd Clarity AD Study Briefing TranscriptNov 30, 2022
- Q2 2023 Eisai Co Ltd Earnings Call TranscriptNov 07, 2022$58.36Earnings
- Eisai Co Ltd Lecanemab Phase 3 Study Met Primary Endpoint Call TranscriptSep 28, 2022
- Q1 2023 Eisai Co Ltd Earnings Call TranscriptAug 05, 2022$46.1Earnings
- Full Year 2022 Eisai Co Ltd Earnings Presentation TranscriptMay 13, 2022
- Eisai Co Ltd Information Meeting TranscriptMar 16, 2022
- Q3 2022 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2022$52.14Earnings
- Q2 2022 Eisai Co Ltd Earnings Call TranscriptNov 01, 2021$70.2Earnings
- Q1 2022 Eisai Co Ltd Earnings Call TranscriptAug 04, 2021$93.97Earnings
- Eisai Co Ltd FDA Grants Accelerated Approval for ADUHELM Presentation TranscriptJun 09, 2021
- Full Year 2021 Eisai Co Ltd Earnings Call TranscriptMay 12, 2021$71.51Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 26, 2021
- Q3 2021 Eisai Co Ltd Earnings Call TranscriptFeb 03, 2021$71.88 (-2.86%)Earnings
- Q2 2021 Eisai Co Ltd Earnings Call TranscriptNov 05, 2020$74.75Earnings
- Q1 2021 Eisai Co Ltd Earnings Call TranscriptAug 03, 2020$80.01Earnings
- Full Year 2020 Eisai Co Ltd Earnings Call TranscriptMay 13, 2020$62 (-17.88%)Earnings
- Eisai Co Ltd Information Meeting TranscriptMar 06, 2020
- Q3 2020 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptJan 31, 2020
- Full Year 2019 Eisai Co Ltd Earnings Presentation and Conference Call TranscriptMay 13, 2019
- Eisai Co Ltd Information Meeting TranscriptMar 08, 2019
Eisai Co Ltd Clarity AD Study Briefing Transcript
Good afternoon, everyone. I welcome to the symposium on Clarity AD, a Phase III placebo-controlled, double-blind, parallel-group, 18 months study evaluating lecanemab in early Alzheimer's disease. I'm Takeshi Iwatsubo from the University of Tokyo. I'm honored and very thrilled to chair this historic session in Alzheimer's research on therapeutics.
Many of you may well remember that on September 27 of this year, the top line results of Clarity AD as a first large completed a positive Phase III trial of disease modifying therapy of AD was announced, which represent a monumental event for patients and their families living with Alzheimer's disease and all scientists in this field, Eisai based in Koishikawa, Tokyo, and then headed by Mr. Haruo Naito, who is also here today, has been at the forefront of Alzheimer's Research over the past 4 decades from developing a symptomatic breakthrough treatment in the 1980s and '90s to the current industry-leading antibody development. The approach rose naturally from the human health care mission.
At this present session, 5 distinguished
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)